Latest Impairment News

archTIS Limited reported a 38% revenue decline and an 11.8% rise in net loss for FY2025, yet achieved positive operating cash flow and secured $7.5 million in new capital to accelerate international expansion.

NeuroScientific Biopharmaceuticals reports encouraging early clinical results for its StemSmart™ MSC therapy in preventing and treating kidney transplant rejection and injury.

KPMG has delivered an unqualified audit opinion on Bathurst Resources Limited’s FY2025 financial statements, while highlighting significant judgment areas around mining asset recoverability and rehabilitation provisions.

Harvest Technology Group reported a reduced net loss of $7.06 million for FY2025 amid restructuring and new funding, while focusing on its remote communications technology segment and launching Project NEON.

Woolworths Group reported a 3.6% normalised sales increase to $69.1 billion for FY25, yet earnings before interest and tax fell 12.6%, weighed down by Australian Food and BIG W segments. The group plans a turnaround in FY26 amid ongoing cost pressures and strategic shifts.

Woolworths Group posted a modest 1.7% revenue increase to $69.1 billion for the 52 weeks ending June 2025, while earnings before interest and tax (EBIT) fell 12.6%, weighed down by challenges in its Australian Food and BIG W segments.

Spirit Technology Solutions reported a 12.7% revenue increase and a 562% surge in underlying EBITDA for FY25, driven by strategic acquisitions that have positioned cyber security as its fastest growing segment.

EML Payments Limited reported a 9% revenue increase and 13% rise in underlying EBITDA for FY25, while advancing its EML2.0 transformation and Project Arlo technology platform. Despite a net loss impacted by a shareholder class action provision, the company’s renewed client pipeline and strategic restructuring signal a pivotal phase ahead.

Mach7 Technologies Limited reported a 16% revenue increase to AUD 33.8 million for FY25, alongside a 22% reduction in net loss, driven by a strategic shift to subscription-based sales and disciplined cost management.

McPherson's Limited reported a 3.9% revenue decline in FY25 driven by exiting lower-margin brands, while core brands grew 1.9%. The company posted a statutory net loss of $15 million, weighed down by significant impairments as it completes a major operating model transformation.

McPherson’s Limited reported a 3.9% revenue decline in FY25 due to shedding non-strategic brands, while its core health and beauty brands grew modestly. The company’s transition to a wholesaler and third-party logistics model marks a pivotal shift aimed at long-term growth despite a widened net loss.

McPherson’s Limited reported a 3.9% revenue decline to $139 million in FY25 amid a strategic shift to a pharmacy wholesaler model, posting a $15 million net loss but signaling moderate EBITDA growth ahead.